Literature DB >> 8522437

Epilarynx: pharynx or larynx?

J L Lefebvre1, E Buisset, B Coche-Dequeant, J T Van, B Prevost, B Hecquet, A Demaille.   

Abstract

BACKGROUND: As a general rule, epilarynx is studied as a part of supraglottis. On the contrary, in France, due to its particular natural history, it is often studied separately.
METHODS: To assess the value of this French classification, we compared from an epidemiologic point of view, in one study, 86 cases of epilarynx squamous cell carcinoma (SCC) with 431 oropharynx, 339 hypopharynx, and 89 vestibule SCC. In another study, we compared, from a clinical point of view, 232 epilarynx SCC with 1351 oropharynx, 652 hypopharynx, and 372 vestibule SCC.
RESULTS: Epilarynx patients appeared to be much heavier drinkers than larynx patients and similar to pharynx patients but tobacco consumption did not differ. The patterns of nodal involvement were similar for pharynx and epilarynx SCC. For stages I and II, patterns of failures were similar, but for stages III and IV, there were fewer locoregional failures in vestibule patients; distant metastases were equally frequent for these tumors. From the standpoint of multiple primaries, epilarynx SCC appeared to be more akin to pharynx than to larynx SCC with a much lower incidence of lung cancers. Finally, the outcome after treatment was different for vestibule, epilarynx, and pharynx SCC, with a 5-year survival of 43%, 27%, and 13%, respectively.
CONCLUSIONS: These data support the identification of epilarynx as a real entity that should be taken into account for stratification in clinical trials.

Entities:  

Mesh:

Year:  1995        PMID: 8522437     DOI: 10.1002/hed.2880170503

Source DB:  PubMed          Journal:  Head Neck        ISSN: 1043-3074            Impact factor:   3.147


  2 in total

1.  Occult metastases from T1-T2 supraglottic carcinoma: role of primary tumor localization.

Authors:  Imdat Yüce; Sedat Cağli; Ali Bayram; Ercihan Güney
Journal:  Eur Arch Otorhinolaryngol       Date:  2008-11-05       Impact factor: 2.503

2.  Platin-based exclusive chemotherapy for selected patients with squamous cell carcinoma of the larynx and pharynx.

Authors:  F Christopher Holsinger; Heather Y Lin; Vincent Bassot; Ollivier Laccourreye
Journal:  Cancer       Date:  2009-09-01       Impact factor: 6.860

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.